Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
vTv Therapeutics ( (VTVT) ) has provided an announcement.
On April 11, 2025, vTv Therapeutics Inc. appointed Barry K. Brown as interim principal financial officer. Mr. Brown, who has been with the company since 2000, has previously served in various financial roles, including as chief accounting officer and interim principal financial officer. The company is actively searching for a permanent chief financial officer through an external process, and Mr. Brown’s appointment was made independently of any external arrangements.
Spark’s Take on VTVT Stock
According to Spark, TipRanks’ AI Analyst, VTVT is a Underperform.
vTv Therapeutics’ overall stock score reflects significant financial difficulties and a speculative valuation, balanced by positive developments in its clinical trials. While the corporate events suggest future potential, the current financial instability and lack of profitability weigh heavily on the stock’s attractiveness.
To see Spark’s full report on VTVT stock, click here.
More about vTv Therapeutics
YTD Price Performance: 33.31%
Average Trading Volume: 23,123
Technical Sentiment Signal: Hold
Current Market Cap: $59.1M
For detailed information about VTVT stock, go to TipRanks’ Stock Analysis page.